Status:
COMPLETED
The Efficacy and Safety of Sildenafil Citrate Used in Combination With Intravenous Epoprostenol in PAH
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Collaborating Sponsors:
Pfizer
Conditions:
Pulmonary Hypertension
Eligibility:
All Genders
16+ years
Phase:
PHASE3
Brief Summary
Determination of the effects of sildenafil citrate and epoprostenol when used in combination in patients with pulmonary arterial hypertension
Eligibility Criteria
Inclusion
- Patients with pulmonary arterial hypertension caused by primary PAH, associated with connective tissue disease or following surgical repair of a congenital heart lesion
Exclusion
- PH other than PAH
Key Trial Info
Start Date :
July 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2006
Estimated Enrollment :
267 Patients enrolled
Trial Details
Trial ID
NCT00159861
Start Date
July 1 2003
End Date
January 1 2006
Last Update
February 1 2021
Active Locations (52)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
La Jolla, California, United States, 92037
2
Pfizer Investigational Site
Los Angeles, California, United States, 90033
3
Pfizer Investigational Site
Los Angeles, California, United States, 90073
4
Pfizer Investigational Site
San Diego, California, United States, 92103